TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1738219
Drug: Albumin supplementation
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin supplementation with total parenteral nutrition
Study: 1738219
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (control group)
Study: 6720727
Drug: Thiazide/propranolol combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide/propranolol combination
Study: 28945652
Drug: Nonpreserved 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpreserved 0.9% NaCl commercial saline solution
Study: 27165064
Drug: Tyrosine kinase
Normalized name: Protein-tyrosine kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitor Votrient
Study: 27165064
Drug: mTOR blocker
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: mTOR blocker Afinitor
Study: 23359971
Drug: Chinese medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medical syndrome typing and treatment combined cold needle puncture drainage operation
Study: 23359971
Drug: Chinese medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medical syndrome typing and treatment combined unipolar electrocoagulation drilling technique
Study: 7530173
Drug: Cisplatin 50
Normalized name: cisplatin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 50 mg/m2 in weeks 1 and 2, IFN 5 MU/m2 per day on days 1-5 in week 1, 5-FU 800 mg/m2 per day for 5 days, HU 500 mg every 12 h for 11 doses during week 2
Study: 7530173
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 during weeks 1 and 2, IFN 2.5 MU/m2 per day
Study: 7530173
Drug: Hyperfractionated radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiotherapy (150 cGy twice daily during weeks 1 and 2)
Study: 7530173
Drug: Chemotherapy doses
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy doses during hyperfractionated radiotherapy
Study: 30767961
Drug: Web-based educational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based educational intervention with tailored messages and quarterly data on hazardous drug spills
Study: 18081224
Drug: Contrast-enhanced ultrasound
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast-enhanced ultrasound with SonoVue (bolus injection 2.5 mL)
Study: 16741726
Drug: Temozolomide (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temozolomide (75 mg/m²/day) for 6 weeks followed by a 2-week rest; Thalidomide (200 mg/day) increased by 100 mg/day weekly up to 400 mg/day (or 100 mg/day increased by 50 mg/day for patients >70 years up to 250 mg/day)
Study: 1883119
Drug: 400 IU
Normalized name: Vitamin D 400 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU of vitamin D daily
Study: 7047256
Drug: guanabenz (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: guanabenz (mean dose, 24 mg/day)
Study: 7047256
Drug: hydrochlorothiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrochlorothiazide (50 or 100 mg/day; mean, 70 mg/day)
Study: 19214338
Drug: Higher protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher protein diet (1.2 +/- 0.0 g protein x kg(-1) x d(-1))
Study: 19214338
Drug: Lower protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower protein diet (0.9 +/- 0.1 g protein x kg(-1) x d(-1))
Study: 10378391
Drug: Acarbose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (50 mg t.i.d.) for 5 days
Study: 6134981
Drug: Selenium levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium levels in serum (mean 0.129 +/- SEM 0.002 micrograms/ml)
Study: 6134981
Drug: Selenium levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium levels in serum (mean 0.136 +/- SEM 0.002 micrograms/ml)
Study: 30133928
Drug: Fosfomycin trometamol
Normalized name: trometamol
DrugBank: Tromethamine (DB03754)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin trometamol (FOS) 3 g PO every 10 days + trimethoprim‐sulfamethoxazole (TMP‐SMX, 160/800 mg) three times per week (Group 1)
Study: 30133928
Drug: Trimethoprim‐sulfamethoxazole (TMP‐SMX,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim‐sulfamethoxazole (TMP‐SMX, 160/800 mg) daily (Group 2)
Study: 20973220
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy group (N)
Study: 16039331
Drug: Carboplatin (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (one injection, dose based on the formula 7x[glomerular filtration rate+25] mg; n=573)
Study: 11942473
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (2-8 g)
Study: 11942473
Drug: Fish meals
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish meals and fish oil supplements
Study: 1761810
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) 0.6 U/kg/week sc 5‐6 times/week
Study: 1761810
Drug: Low-dose oxandrolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oxandrolone 0.07 mg/kg po
Study: 6366806
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg salbutamol 3-times daily
Study: 6366806
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms clenbuterol twice daily
Study: 6366806
Drug: 40 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 micrograms clenbuterol twice daily
Study: 25098981
Drug: Levamisole (vermisole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (vermisole 150 mg, once daily for the first 3 days of 3 weeks in a month for 3 months with a gap of 1 week)
Study: 22212648
Drug: pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pegylated interferon alpha plus ribavirin therapy
Study: 15498373
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and moxibustion (acu‐moxi) in combination with prednisone, Vitamin B1, vitamin B12, and dibazole
Study: 10694777
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea (2 g tea solids in 300 ml water)
Study: 1389935
Drug: Sublingual verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual verapamil 40 mg (Securon)
Study: 1389935
Drug: Oral verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral verapamil 40 mg (Securon)
Study: 17583595
Drug: Esmolol 1
Normalized name: esmolol 10 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 1 mg kg‐1 (Group I, n = 40)
Study: 17583595
Drug: Magnesium 30
Normalized name: Magnesium 30mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium 30 mg kg‐1 (Group II, n = 40)
Study: 12197844
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 mg twice daily for 8 weeks)
Study: 12197844
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical capsules for 8 weeks)
Study: 9451563
Drug: Fine-needle aspiration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fine-needle aspiration (FNA) sampling from 3 sequential regions
Study: 9451563
Drug: Fine-needle aspiration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fine-needle aspiration (FNA) sampling from 4 sequential regions
Study: 30773863
Drug: IHTAN +
Approvals — FDA: no, EMA: no, PMDA: no
Description: IHTAN + acupoint injection
Study: 30773863
Drug: Warm needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm needle moxibustion + acupoint injection
Study: 20808092
Drug: Home-delivered problem
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home-delivered problem adaptation therapy (PATH)
Study: 20808092
Drug: Home-delivered supportive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-delivered supportive therapy (ST)
Study: 17209889
Drug: Spaced education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spaced education consisting of weekly e-mailed case scenarios and clinical questions on 2 of the 4 urology topics.
Study: 12934761
Drug: E-Mousse (20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: E-Mousse (20% acetate vitamin E) applied twice daily for 3 weeks
Study: 1913767
Drug: Least thorough
Approvals — FDA: no, EMA: no, PMDA: no
Description: Least thorough rinsing procedure (5 ml x 2 s once)
Study: 1913767
Drug: Most thorough
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Most thorough rinsing procedure (20 ml x 10 s twice)
Study: 6130066
Drug: buspirone (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: buspirone (average 16.5 mg/day)
Study: 6130066
Drug: diazepam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam (15 mg/day)
Study: 30880505
Drug: 550 mg
Normalized name: xylitol 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 550 mg of MYO + 150 mg of DCI twice daily
Study: 30880505
Drug: 550 mg
Normalized name: xylitol 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 550 mg of MYO + 13.8 mg of DCI twice daily
Study: 26850310
Drug: Weekly nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly nutrition lessons focused on benefits of fruit and vegetable consumption
Study: 26850310
Drug: Weekly nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly nutrition lessons and provision of one serving of fruits and two servings of vegetables per day for 10 weeks
Study: 21819279
Drug: Methylphenidate treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate treatment for 10 weeks
Study: 15755866
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (850 mg/d)
Study: 7893868
Drug: Ceftazidime (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (120 mg/[kg.d])
Study: 7893868
Drug: Amoxicillin/clavulanate (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (160 mg/[kg.d])
Study: 2447403
Drug: epanolol, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: epanolol, 200 mg b.i.d.
Study: 2447403
Drug: pindolol, 10
Normalized name: Pindolol, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: pindolol, 10 mg b.i.d.
Study: 2447403
Drug: epanolol, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: epanolol, 400 mg q.d.
Study: 2447403
Drug: pindolol, 10
Normalized name: Pindolol, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: pindolol, 10 mg b.i.d. and epanolol, 200 mg b.i.d.
Study: 29608967
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in older patients (65 years and older)
Study: 29608967
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in younger patients (younger than 65 years)
Study: 22561596
Drug: Desmopressin (DDAVP)
Normalized name: desmopressin Injection [DDAVP]
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Desmopressin (DDAVP) 0.2 mg orally
Study: 17991531
Drug: 3-day standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day standard bowel preparation (group 1)
Study: 17991531
Drug: Soft diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft diet with no oral intake 8 hours before surgery (group 2)
Study: 12006190
Drug: 532 nm,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 532 nm, 2 ms pulse-duration Nd:YAG laser treatment for upper lip wrinkles
Study: 12006190
Drug: 532 nm,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 532 nm, 2 ms pulse-duration Nd:YAG laser treatment for facial acne scarring
Study: 9893933
Drug: Test 1
Normalized name: Bar Test 10% Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test 1 (chewable tablets containing 76 mg Na2FPO3 and 1250 mg calcium carbonate)
Study: 9893933
Drug: Test 2
Normalized name: Methitest 25mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test 2 (effervescent tablets containing 76 mg Na2FPO3 and 1250 mg calcium carbonate)
Study: 9893933
Drug: Ref1 (tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ref1 (tablets containing 76 mg Na2FPO3)
Study: 9893933
Drug: Ref2 (effervescent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ref2 (effervescent tablets containing 76 mg Na2FPO3 and 3240 mg calcium lactogluconate/carbonate)
Study: 2840815
Drug: Lisinopril 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 5.0 mg
Study: 2840815
Drug: Lisinopril (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (various doses)
Study: 8018302
Drug: Drug treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatments to reduce hypertension and hyperlipidaemia
Study: 368370
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C prophylaxis, 2.0 g/day
Study: 31794152
Drug: Zinc acetate
Normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc acetate hydrate (ZAH; 50 mg/day)
Study: 31794152
Drug: Polaprezinc (PPZ;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polaprezinc (PPZ; 34 mg/day)
Study: 27638233
Drug: Deterioration in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deterioration in eGFR >15 mL•min‐1•1.73 m‐2 in the 1st 12 months
Study: 27638233
Drug: Deterioration in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deterioration in eGFR >15 mL•min‐1•1.73 m‐2 in the 1st year
Study: 25794285
Drug: Escitalopram (10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10.0 ± 4.0 mg/day)
Study: 25794285
Drug: Sertraline (78.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (78.6 ± 26.7 mg/day)
Study: 25794285
Drug: Paroxetine controlled-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine controlled-release formulation (18.8 ± 8.8 mg/day)
Study: 19557566
Drug: Infrared (IR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infrared (IR) treatment for 20 minutes
Study: 19557566
Drug: Therapeutic ultrasound
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic ultrasound (US) treatment for 10 minutes
Study: 16129844
Drug: G‐CSF schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF schedule 5 (300 microg/d days 8 and 12)
Study: 16129844
Drug: G‐CSF (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (any schedule)
Study: 11166906
Drug: vCP205 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: vCP205 and SF-2 rgp120 subunit vaccines
Study: 21158953
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of ascorbic acid (AA)/kg diet
Study: 12805552
Drug: Sequential presentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential presentation of the stimulus at one location
Study: 7742084
Drug: 1,25(OH)2D3 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25(OH)2D3 treatment
Study: 2043077
Drug: Antibiotic rinse/storage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic rinse/storage (neomycin‐polymyxin B‐gramicidin)
Study: 7028312
Drug: Cimetidine and
Normalized name: Cimetidine and sodium alginate only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine and Promethazine combination
Study: 24126895
Drug: NaHCO3 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaHCO3 (0.3 g·kg(‐1) body mass)
Study: 24126895
Drug: Placebo (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sodium chloride NaCl: 0.045 g·kg(‐1) body mass)
Study: 20543025
Drug: Conversation intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conversation intervention (500 min of linguistically and cognitively complex talk over 10 weeks, 25 min twice weekly)
Study: 12028854
Drug: 4 or
Normalized name: Dex4 Orange
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 or 8 mg/day of buprenorphine
Study: 7670648
Drug: ACE-inhibitor (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-inhibitor (n = 135)
Study: 7670648
Drug: Calcium-antagonist (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-antagonist (n = 131)
Study: 7670648
Drug: ACE-inhibitor and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-inhibitor and Calcium-antagonist
Study: 2166885
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (NS) 4 mg four times daily
Study: 2166885
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BD) 0.1 mg four times daily
Study: 17400089
Drug: PS implants
Normalized name: PS
DrugBank: Phosphatidyl serine (DB00144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PS implants designed for increased flexion
Study: 17400089
Drug: Standard posterior-stabilized
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard posterior-stabilized (PS) implants
Study: 16350714
Drug: 1alpha‐OHD3 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1alpha‐OHD3 (0.5 microg/d) and calcium carbonate (1 g daily)
Study: 16350714
Drug: Complete androgenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete androgenic blockade (orchidectomy + flutamide 750 mg daily)
Study: 1729065
Drug: Amrinone (2.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrinone (2.25 mg/kg bolus + 20 micrograms/kg/min)
Study: 6741156
Drug: Traditional prolonged-action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional prolonged-action theophylline-ethylenediamine preparation
Study: 31248307
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (233 mg zinc gluconate containing 30 mg zinc) for 10 weeks
Study: 29224639
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care medication
Study: 26742777
Drug: Lesinurad 200
Normalized name: lesinurad 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesinurad 200 mg/day in combination with allopurinol
Study: 26742777
Drug: Lesinurad 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesinurad 400 mg/day in combination with allopurinol
Study: 26742777
Drug: Lesinurad 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesinurad 600 mg/day in combination with allopurinol
Study: 26742777
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with allopurinol
Study: 14967866
Drug: 8% CHOexo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% CHOexo (1 g glucose x kg x h(‐1))
Study: 10758775
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (Azectol)
Study: 3040918
Drug: All four
Normalized name: Jackson's The Original All Fours
Approvals — FDA: no, EMA: no, PMDA: no
Description: All four drugs (VDS, CCNU, CTX, MTX)
Study: 3040918
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with dose‐limiting toxicity
Study: 26928185
Drug: Intraoperative periarticular
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative periarticular injection (PAI)
Study: 10230948
Drug: Low-dose propofol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose propofol infusion (1 mg/kg/h)
Study: 10230948
Drug: Low-dose propofol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose propofol infusion
Study: 1524328
Drug: Selective decontamination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective decontamination of the digestive tract using cefotaxime (1 g IV every 8 hours for the first 3 days) and oral nonabsorbable antibiotics (gentamicin, polymyxin, and nystatin) for the entire stay in the ICU
Study: 6231062
Drug: Micronized etodolac
Normalized name: Etodolac
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micronized etodolac in capsule and tablet forms
Study: 6231062
Drug: Regular etodolac
Normalized name: Etodolac
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regular etodolac dosage forms
Study: 6231062
Drug: Etodolac with
Normalized name: Etodolac
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etodolac with antacid (magaldrate)
Study: 6231062
Drug: Etodolac with
Normalized name: Etodolac
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etodolac with antiulcer agent (sucralfate)
Study: 6231062
Drug: Single bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus dose or divided (b.i.d.) doses of etodolac in man
Study: 31697698
Drug: GOAL program
Approvals — FDA: no, EMA: no, PMDA: no
Description: GOAL program (twice weekly group sessions for 10 weeks, 20 sessions)
Study: 27322638
Drug: Blood alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blood alcohol concentration (BAC) of approx. 0.5g/L
Study: 27322638
Drug: Blood alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blood alcohol concentration (BAC) of approx. 0.9g/L
Study: 19255158
Drug: Monthly intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly intravitreal ranibizumab (0.3 or 0.5 mg)
Study: 19255158
Drug: Sham injections
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injections (control group in MARINA)
Study: 19255158
Drug: Monthly ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monthly ranibizumab (0.3 or 0.5 mg) with sham photodynamic therapy (PDT)
Study: 19255158
Drug: Sham ocular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham ocular injections with verteporfin PDT (control group in ANCHOR)
Study: 17720114
Drug: HPbetaCD diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPbetaCD diclofenac sodium 75 mg
Study: 17720114
Drug: PG‐BA diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: PG‐BA diclofenac sodium 75 mg